NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/TRIM24

Cancer Biotherapy and Radiopharmaceuticals - United States
doi 10.1089/cbr.2019.3054
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Long Non-Coding RNA NCK1-AS1 Promotes the Tumorigenesis of Glioma Through Sponging microRNA-138-2-3p and Activating the TRIM24/Wnt/β-catenin Axis

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2020English

Silencing LDHA Inhibits Proliferation, Induces Apoptosis and Increases Chemosensitivity to Temozolomide in Glioma Cells

Oncology Letters
Cancer ResearchOncology
2018English

Knockdown of Long Non-Coding RNA XIST Increases Blood–tumor Barrier Permeability and Inhibits Glioma Angiogenesis by Targeting miR-137

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Inhibition of Telomerase Increases Resistance of Melanoma Cells to Temozolomide, but Not to Temozolomide Combined With Poly (ADP-Ribose) Polymerase Inhibitor

Molecular Pharmacology
Molecular MedicinePharmacology
2003English

H19 Induced by Oxidative Stress Confers Temozolomide Resistance in Human Glioma Cells via Activating NF-κB Signaling

OncoTargets and Therapy
OncologyPharmacology
2018English

PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

HNF1A-AS1 Regulates Cell Migration, Invasion and Glycolysis via Modulating miR-124/MYO6 in Colorectal Cancer Cells

OncoTargets and Therapy
OncologyPharmacology
2020English

lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424

OncoTargets and Therapy
OncologyPharmacology
2020English

LncRNA ZEB2-AS1 Regulates the Drug Resistance of Acute Myeloid Leukemia via the miR-142-3p/INPP4B Axis

RSC Advances
ChemistryChemical Engineering
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy